Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2001
12/06/2001WO2001091780A1 Neuroprotective peptides
12/06/2001WO2001091779A1 Remedies for corneal injuries
12/06/2001WO2001091774A2 Method of treating chronic ulcers
12/06/2001WO2001091773A2 Method of stimulating hair growth
12/06/2001WO2001091762A1 Zinc-supplementary compositions for oral administration
12/06/2001WO2001091739A2 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
12/06/2001WO2001091719A1 Nasal ointment based on white petroleum jelly
12/06/2001WO2001091713A1 Cosmetic composition comprising human serum albumin obtained from transgenic non-human animals
12/06/2001WO2001091711A1 Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases
12/06/2001WO2001091700A2 Composition and method for enhancing elasticity of tissue
12/06/2001WO2001091699A2 Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
12/06/2001WO2001091698A2 Genetically-engineered mhc molecules
12/06/2001WO2001091633A1 A formula to manipulate blood glucose via the calculated ingestion of carbohydrate
12/06/2001WO2001091588A1 Primary composition containing a lipophilic bioactive compound
12/06/2001WO2001068805A8 Human olfactory receptors and genes encoding same
12/06/2001WO2001064922A3 Heterologous expression of neisserial proteins
12/06/2001WO2001060837A3 Polypeptoid pulmonary surfactants
12/06/2001WO2001060339A3 Method for the preparation of microspheres which contain colloidal systems
12/06/2001WO2001057271A8 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human breast and bt 474 cells
12/06/2001WO2001056532A3 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
12/06/2001WO2001055387A8 Nucleic acids, proteins, and antibodies
12/06/2001WO2001055313A8 Nucleic acids, proteins, and antibodies
12/06/2001WO2001053500A8 Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides
12/06/2001WO2001053351A3 Apoptin bindendes protein
12/06/2001WO2001052875A8 Vegf-d/vegf-c/vegf peptidomimetic inhibitor
12/06/2001WO2001047546A3 Methods and products for tumor immunotherapy using cytokines
12/06/2001WO2001046392A3 Homologues of human heparanase and splice variants thereof
12/06/2001WO2001046225A3 Chlamydia antigens and corresponding dna fragments and uses thereof
12/06/2001WO2001046224A3 Chlamydia antigens and corresponding dna fragments and uses thereof
12/06/2001WO2001045732A3 Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections
12/06/2001WO2001044443A3 Cytochrome p450rai-2 and related proteins
12/06/2001WO2001041704A3 Method for the prevention and/or treatment of atherosclerosis
12/06/2001WO2001034646A3 Recombinant gelatins
12/06/2001WO2001034181A3 Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene
12/06/2001WO2001034138B1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
12/06/2001WO2001030991A3 Human narcolepsy gene
12/06/2001WO2001030854A3 Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin
12/06/2001WO2001030376A3 Use of urodilatin for treating chronic kidney failure with residual kidney functions
12/06/2001WO2001025390B1 Water unstable foam compositions
12/06/2001WO2001025257A3 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
12/06/2001WO2001023553A9 Metastasis-associated antigen c4.4a
12/06/2001WO2001023421B1 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
12/06/2001WO2001021653A3 Ovarian tumor antigen and methods of use therefor
12/06/2001WO2001018042A3 Apoptosis proteins
12/06/2001WO2001016345A3 Sequence-specific dna recombination in eukaryotic cells
12/06/2001WO2001012775A8 25 human secreted proteins
12/06/2001WO2001012662A3 Membrane associated proteins
12/06/2001WO2001005432A3 Conjugate for mediating cell, compartment or membrane-specific transport of active substances
12/06/2001WO2000072868A3 Peptides for therapeutic use
12/06/2001WO2000050443A9 Secreted proteins and uses thereof
12/06/2001WO2000038517A9 Methods for reducing adverse side effects associated with cellular transplantation
12/06/2001WO2000025804A9 A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
12/06/2001WO2000011166A9 14274 receptor, a g-protein coupled receptor related to the edg receptor family
12/06/2001WO2000011036A9 AN ANTI-CYANOVIRIN ANTIBODY WITH AN INTERNAL IMAGE OF gp120, A METHOD OF USE THEREOF, AND A METHOD OF USING A CYANOVIRIN TO INDUCE AN IMMUNE RESPONSE TO gp120
12/06/2001WO2000006599A8 Inhibitors of hiv membrane fusion
12/06/2001WO1997017448A3 Calcium independent cytosolic phospholipase a2/b enzymes
12/06/2001US20010049829 Developmental competence for assisted reproduction and nuclear transfer in pigs
12/06/2001US20010049359 Treatment of hiv infection
12/06/2001US20010049357 Promotes dendritic cell maturation in vitro.
12/06/2001US20010049356 Method of preparing fetuin to induce apoptosis
12/06/2001US20010049355 Providing exogenous SLED to endothelial cells; maybe be provided systemically, topically, or via a vector comprising a SLED expression cassette
12/06/2001US20010049354 Protecting solid-state proteins from the effects of ionizing radiation
12/06/2001US20010049353 Stimulating secretion of pancreatic juices
12/06/2001US20010049352 Hydrolyzed whey protein; a carbohydrate source; and a lipid source including a mixture of medium and long chain triglycerides; caloric density of at least 1.4 kcal/mL; ratio of non-protein calories per gram nitrogen of at least 90:1.
12/06/2001US20010049351 Method of determining down-regulation of the expression of hiv coreceptor, ccr5 with product r
12/06/2001US20010049349 Antioxidant enhancement of therapy for hyperproliferative conditions
12/06/2001US20010049142 A rapid, simple-to-use method to differentiate nondividing cells by fusing two different cells and then purifying them without antibiotic or metabolic selection; kits with two nontoxic dyes and instructions; antitumor agents
12/06/2001US20010049136 Deletion of: all or part of the E1A regions, the E1B region coding for the early proteins, E2 or E4 regions, the E1a region and encapsidation region; gene therapy
12/06/2001US20010049122 For reducing inflammation, for treating an autoimmune disease, for enhancing transplantation of tissue grafts, increasing antitumor immunity, and inhibiting viral and parasitic infections
12/06/2001US20010049121 Polypeptides and polynucleotides; drug screening, use in therapy, diagnostic assays
12/06/2001US20010049107 Patient-specific library of antineoplastic antibodies or fragments; variable regions are linked, cloned into expression vectors, amplified; libraries transferred to other expression vectors without losing diversity
12/06/2001US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases
12/06/2001US20010049093 Inhibition of viral gene activities
12/06/2001US20010048952 Mixture of aloe vera, collagen, chromium compounds and linoleic acid
12/06/2001US20010048948 Intestine health; immunology; mixture containing whey
12/06/2001US20010048947 Drug delivery
12/06/2001US20010048925 Core or carrier adjuvant for vaccine
12/06/2001US20010048924 Method for inhibiting cerebral tissue factor mediated reperfusion damage
12/06/2001US20010048923 Immune cell regulation with src ptk sequestering agents
12/06/2001US20010048915 Decreased endogenous nitric oxide activation
12/06/2001DE10025464A1 Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen Combined use of enzyme inhibitors for the therapy of autoimmune diseases, transplantation and tumor diseases as well as combinations of enzyme inhibitors pharmaceutical preparations comprising
12/06/2001DE10025152A1 Treatment of noise- or age-induced hearing deficiency, comprises using neurotrophin stimulating agents to counteract cochlear neurodegeneration
12/06/2001CA2415225A1 Composition and method for enhancing elasticity of tissue
12/06/2001CA2414207A1 Adjuvant preparation for the induction of specific immunity
12/06/2001CA2413188A1 Petrolatum-based nose ointment
12/06/2001CA2411667A1 Ghrelin analogs
12/06/2001CA2411666A1 Methods and compositions for producing a neurosalutary effect in a subject
12/06/2001CA2411404A1 Compositions and methods for the therapy and diagnosis of ovarian cancer
12/06/2001CA2411040A1 Therapeutic anti-melanoma compounds
12/06/2001CA2410981A1 Adenovirus particles with mutagenized fiber proteins
12/06/2001CA2410949A1 Novel target genes for diseases of the heart
12/06/2001CA2410912A1 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
12/06/2001CA2410895A1 Therapeutic compounds for ovarian cancer
12/06/2001CA2410865A1 Therapeutic compounds for ovarian cancer
12/06/2001CA2410762A1 Feline hepatocyte growth factor
12/06/2001CA2410758A1 Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation
12/06/2001CA2410736A1 Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof
12/06/2001CA2410735A1 Use of adnf for enhancing learning and memory
12/06/2001CA2410591A1 Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases
12/06/2001CA2410523A1 Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides